International Journal of Clinical Oncology

, Volume 23, Issue 5, pp 1007–1013 | Cite as

Effect of post-filter anticoagulation on mortality in patients with cancer-associated pulmonary embolism

  • Jieun Kang
  • Seon Ok Kim
  • Yeon-Mok Oh
  • Sang-Do Lee
  • Jae Seung Lee
Original Article



Malignancy is associated with an increased risk of venous thromboembolism. Inferior vena cava filters are a viable alternative when anticoagulation is infeasible because of the risk of bleeding. Although the current guidelines recommend that all patients with a vena cava filter be treated with anticoagulation treatment when the risk of bleeding is reduced, studies concerning the role of concomitant anticoagulation after vena cava filter insertion in high-risk patients are scarce. Since many cancer patients suffer from a high risk of hemorrhagic complications, we aimed to determine the effect of post-filter anticoagulation on mortality in patients with a malignant solid tumor.


A retrospective cohort study of patients with pulmonary embolism was performed between January 2010 and May 2016. Patients with a solid tumor and vena cava filter inserted because of pulmonary embolism were included. Using Cox proportional hazards model, the prognostic effect of clinical variables was analyzed.


A total of 180 patients were analyzed, with 143 patients receiving and 37 patients not receiving post-filter anticoagulation treatment. Mortality was not significantly different between the two groups. The presence of metastatic cancer and that of pancreatobiliary cancer were significant risk factors for mortality. However, post-filter anticoagulation did not show significant effect on mortality regardless of the stage of cancer.


In patients with cancer-associated pulmonary embolism, the effect of post-filter anticoagulation on mortality may not be critical, especially in patients with a short life expectancy.


Pulmonary embolism Venous thromboembolism Vena cava filters Anticoagulation 



This study was supported by University of Ulsan College of Medicine.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

10147_2018_1290_MOESM1_ESM.docx (27 kb)
Supplementary material 1 (DOCX 27 KB)


  1. 1.
    Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. Jama 293(6):715–722. CrossRefPubMedGoogle Scholar
  2. 2.
    Cronin-Fenton DP, Sondergaard F, Pedersen LA et al (2010) Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. Br J Cancer 103(7):947–953. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Heit JA, O’Fallon WM, Petterson TM et al (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162(11):1245–1248CrossRefPubMedGoogle Scholar
  4. 4.
    Stein PD, Kayali F, Olson RE (2004) Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med 164(14):1541–1545. CrossRefPubMedGoogle Scholar
  5. 5.
    Kaufman JA, Kinney TB, Streiff MB et al (2006) Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. J Vasc Interv Radiol 17(3):449–459. CrossRefPubMedGoogle Scholar
  6. 6.
    Group PS (2005) Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d’Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 112(3):416–422. CrossRefGoogle Scholar
  7. 7.
    Kearon C, Akl EA, American College of Chest P et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e419S-494S. CrossRefGoogle Scholar
  8. 8.
    Caine GJ, Stonelake PS, Lip GY, Kehoe ST (2002) The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia (New York NY) 4(6):465–473. CrossRefGoogle Scholar
  9. 9.
    Kamphuisen PW, Beyer-Westendorf J (2014) Bleeding complications during anticoagulant treatment in patients with cancer. Thromb Res 133(Suppl 2):S49-55. CrossRefPubMedGoogle Scholar
  10. 10.
    Ray CE, Mitchell E, Zipser S et al (2006) Outcomes with retrievable inferior vena cava filters: a multicenter study. J Vasc Interv Radiol 17(10):1595–1604. CrossRefPubMedGoogle Scholar
  11. 11.
    Ray CE, Prochazka A (2008) The need for anticoagulation following inferior vena cava filter placement: systematic review. Cardiovasc Intervent Radiol 31(2):316–324. CrossRefPubMedGoogle Scholar
  12. 12.
    Greenfield LJ, Proctor MC (2001) Recurrent thromboembolism in patients with vena cava filters. J Vasc Surg 33(3):510–514. CrossRefPubMedGoogle Scholar
  13. 13.
    Dovrish Z, Hadary R, Blickstein D, Shilo L, Ellis MH (2006) Retrospective analysis of the use of inferior vena cava filters in routine hospital practice. Postgrad Med J 82(964):150–153. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Yale SH, Mazza JJ, Glurich I et al (2006) Recurrent venous thromboembolism in patients with and without anticoagulation after inferior vena caval filter placement. Int Angiol 25(1):60–66PubMedGoogle Scholar
  15. 15.
    Charlson ME, Sax FL, MacKenzie CR et al (1987) Morbidity during hospitalization: can we predict it? J Chronic Dis 40(7):705–712CrossRefPubMedGoogle Scholar
  16. 16.
    Jimenez D, Aujesky D, Moores L et al (2010) Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 170(15):1383–1389. CrossRefPubMedGoogle Scholar
  17. 17.
    Chow FC, Chan YC, Cheung GC et al (2015) Mid- and long-term outcome of patients with permanent inferior vena cava filters: a single center review. Ann Vasc Surg 29(5):985–994. CrossRefPubMedGoogle Scholar
  18. 18.
    Cugell DW (1993) Vena caval filters and anticoagulants for pulmonary emboli. Jama 270(15):1867–1868PubMedGoogle Scholar
  19. 19.
    Falatko JM, Dalal B, Qu L (2017) Impact of anticoagulation in elderly patients with pulmonary embolism that undergo IVC filter placement: A Retrospective Cohort Study. Heart Lung Circ. CrossRefPubMedGoogle Scholar
  20. 20.
    Mandala M, Falanga A, Roila F et al (2011) Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 6(22):vi85-92. CrossRefGoogle Scholar
  21. 21.
    Streiff MB, Bockenstedt PL, Cataland SR et al. (2013) Venous thromboembolic disease. JNCCN 11(11):1402–1429PubMedGoogle Scholar
  22. 22.
    Kroll MH, Pemmaraju N, Oo TH et al (2014) Mortality from cancer-associated venous thromboembolism. Blood 124(21):4829–4829Google Scholar

Copyright information

© Japan Society of Clinical Oncology 2018

Authors and Affiliations

  • Jieun Kang
    • 1
  • Seon Ok Kim
    • 2
  • Yeon-Mok Oh
    • 1
  • Sang-Do Lee
    • 1
  • Jae Seung Lee
    • 1
    • 3
  1. 1.Department of Pulmonary and Critical Care Medicine, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulSouth Korea
  2. 2.Department of Clinical Epidemiology and BiostatisticsAsan Medical CenterSeoulSouth Korea
  3. 3.Center for Pulmonary Hypertension and Venous Thrombosis, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulSouth Korea

Personalised recommendations